Events in 2022

13.00 How the UK IVD industry responded to the pandemic
Lord Bethell
13.30 Pathology GIRFT: Next steps and implementing the recommendations Dr Martin Myers, Dr Marion Wood and Tom Lewis, NHS England and Improvement
14.00 Pathology Quality Assurance Dashboard: The Early years
Jane Mills & Bruce Daniel, NHS England and Improvement
14.30 Pathology Networks: maturity, future strategy & enablers
Jane Mills, NHS England and Improvement
15.45 Pathology Networks: Developing our people, strategy and planning
Bruce Daniel, Suchita Joshi & Divine Azange
16.15 The pathology portal
Professor Jo Martin, NHS England and Improvement

13.00 ISO 15189 it’s all about the patient: What to expect from the new version
Dr David Ricketts, Health Services Laboratories LLP
13.30 Quality for the patient, not just for the sake of it
Shauna McAuley, Belfast Health and Social Care Trust
14.00 Learning from excellence – recognising when things go right Dr Adrian Plunkett, Learning from
Excellence, Birmingham Women’s and Children’s NHS Foundation Trust
14.30 Investigation of serious incidents
– what to do when things go wrong Nigel Coles, Birmingham Women’s and Children’s NHS Foundation Trust
15.45 Ensuring quality in an emergency situation
Jessica Dixon, Milton Keynes University Hospital NHS Foundation Trust
16.15 Maintaining a permanent state of readiness
John Ringrow, UKAS
16.45 Remote auditing
David Wilson, IBMS Specialist Advisor, Immunology

Chair: Tony Dedman
9.00 Monitoring asparaginase activity to inform treatment of acute lymphoblastic leukaemia
Dr Jonathan Lambert, Great Ormond Street Hospital for Children NHS Foundation Trust
9.30 How will the challenges of the pandemic impact how we offer future Clinical Biochemistry services? Dr David Ricketts, Health Services Laboratories LLP
10.30 Harveys Gang: From the lab to the ward
Sophie Ward, NorthWest London Pathology, Charing Cross Hospital London
11.00 Spectrum of conditions associated with paraproteins: From laboratory to the clinic
Dr Aaron Niblock, Antrim Area Hospital, Northern Health and Social Care Trust 11.30 Cerebrospinal fluid (CSF) biomarkers in the investigation
of patients with dementia
Dr Alison Green, University of Edinburgh
12.45 Demand optimisation in a post- COVID world
Claire Lawrie, NHS National Services Scotland

13.30 Influenza-like-Illness testing and its importance as SARS-CoV-2 moves from pandemic to endemic Gavin Wall MSc MBA DipRCPath, Director of Medical Affairs (Infectious Diseases), QIAGEN

13.00 Introducing the PATHFAST™
- Emergency Marker High Sensitivity Troponin I assay into the Emergency Department
Ian Smith, AB Scientific

14.30 Data Driven Pathology Martin Wilkinson, Director of Product Introduction, Strategy and User Adoption, InterSystems

14.00 The next revolution in infectious disease testing -
integrating prognosis and diagnosis by reading the host response
Dr. Florian Uhle. Inflammatix, Associate Director Medical Affairs Europe, Pro-Lab Diagnostics

15.00 Bringing Fungal Diagnostics In-House Andrew Wood, General Manager, BioConnections

16.30 East Kent Hospital inactivate SARS-CoV-2 in 60secs, revolutionising their workflow processes.
Michael Dawson, Medical Wire Equipment

16.00 Quality improvement in the pre-analytical phase
Fabio Sgarabottolo, A. Menarini Diagnostics